Triggering receptor expressed on myeloid cells-like transcript 1 receptor (TLT-1)

Triggering receptor expressed on myeloid cells-like transcript 1 receptor (TLT-1) is a type I transmembrane receptor belonging to the immunoglobulin superfamily, encoded by the TREML1 gene on chromosome 6 in humans[5]. TLT-1 is a single Ig domain orphan receptor, expressed specifically in platelets and megakaryocytes, where it resides in α-granules and is translocated to the cell surface upon platelet activation (by stimuli like thrombin or LPS)[1][7]. It plays a key role in hemostasis by enhancing platelet aggregation and facilitating actin polymerization, thereby supporting vascular integrity. TLT-1's cytoplasmic tail interacts with ERM proteins, guiding rapid platelet pseudopodia formation. A soluble fragment (sTLT-1) is released into the serum following activation, which can further enhance aggregation and modulate inflammatory responses. TLT-1 has been linked to both promoting and protecting against thrombosis, hemorrhage, and inflammatory disease, making it a potential therapeutic target for conditions like sepsis, atherothrombosis, and cardiovascular disease[1][2][7][8].

Other names

TREM-like transcript-1TREML1TLT-1TLT1triggering receptor expressed on myeloid cells like 1GLTL1825PRO3438dJ238O23.3[5][1][7]

Blocking TLT-1 (by scFv or inhibitory peptides) can inhibit thrombin-mediated platelet aggregation and clot retraction[2]. Potential future drugs could act by modulating TLT-1's role in platelet function, coagulation, or inflammatory signaling.